<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921414</url>
  </required_header>
  <id_info>
    <org_study_id>Manteau 2007 SJ &quot;LYMA&quot;</org_study_id>
    <nct_id>NCT00921414</nct_id>
  </id_info>
  <brief_title>Mantel Cell Lymphoma Efficacy of Rituximab Maintenance</brief_title>
  <official_title>Manteau 2007 SJ &quot;LYMA&quot; &quot;Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, open-label, phase III study to evaluate the efficacy of rituximab maintenance
      therapy in patients aged between 18 and 65 years inclusive undergoing first-line treatment
      for mantle cell lymphoma and exhibiting a response after autologous transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Demonstration of the superiority in terms of 4-year event-free survival (EFS) of Rituximab
      maintenance therapy compared to post-autograft surveillance in patients aged 18-65 years
      inclusive, treated with R-DHAP then autologous transplantation for MCL as first-line therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event-free survival (EFS) post Rituximab maintenance therapy</measure>
    <time_frame>EFS post 4 years after maintenance</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of PFS of the entire group of patients.</measure>
    <time_frame>Safety/efficacy of maintenance treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of OS of the entire group of patients</measure>
    <time_frame>safety/efficacy of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete, partial and overall response rate after induction with R-DHAP and after ASCT.</measure>
    <time_frame>safety/efficacy of all the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>observation : 3 years maintenance period with assesments and surveillance every 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Mabthera®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Watch and wait</intervention_name>
    <description>No treatment patient follow-up every 2 months during 3 years</description>
    <arm_group_label>1</arm_group_label>
    <other_name>observation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mantle cell lymphoma

          -  Initial immunophenotyping with CD20 and CD5.

          -  CD20+.

          -  t (11;14) by karyote, FISH, molecular biology or immunohistochemistry (Bcl-1)

          -  Patient no previous treated.

          -  At least one tumor site accessible for assessment

          -  Aged &gt; 18 years &lt; 65

          -  ECOG &lt; or = 2.

          -  No other neoplasms apart from resected basal cell carcinoma or in situ carcinoma.

          -  signed informed consent

          -  FEVG 50%

        Exclusion Criteria:

          -  other type of lymphoma

          -  ECOG &gt; or = 3

          -  relapse

          -  serology VIH + Hepatite +

          -  diabetis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven LE GOUILL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO Website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>R DHAP</keyword>
  <keyword>ASCT</keyword>
  <keyword>Rituximab Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

